How to translate your oncology target into a preclinical candidate (PART 2)
With a focus on oncology research, we will explain how to de-risk your drug discovery programs.
Based on your feedback from the last NUVISAN talk, we designed a follow-up talk focusing on the obstacles you may encounter when developing a novel preclinical compound.
By going deeper into recent drug discovery programs, we will exemplify how NUVISAN approaches these challenges. In our examples, we will show how to identify novel small molecule inhibitors by a phenotypic screening approach and how to deconvolute the underlying target. Furthermore, we will show how to come to a deeper understanding of the Mode of Action of a novel compound class. Finally, we will show how to assess the therapeutic potential and the PK/PD relationship of novel compounds in vivo.
In a Q&A session following the presentation, 15 minutes will be allocated to further discuss.
Interested in learning how to accelerate your drug discovery program in oncology and lower your attrition rate?
In this 45-minute presentation, Dr. Martin Lange, Head of Translational Research, and Dr. Carlo Stresemann, Head of Therapeutic Oncology Research, will cover:
• Our services at NUVISAN-ICB
• Target deconvolution of novel compounds
• Elucidating mechanism of actions (MoA) of novel compounds
• In vivo profiling of novel compounds
• Live Q&A session
